Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Concord Biotech IPO is a book build issue of ₹1,550.52 crores. The issue is entirely an offer for sale of 2.09 crore shares of ₹1,550.52 crore.
Concord Biotech IPO bidding started from Aug 4, 2023 and ended on Aug 8, 2023. The allotment for Concord Biotech IPO was finalized on Aug 11, 2023. The shares got listed on BSE, NSE on Aug 18, 2023.
Concord Biotech IPO price band is set at ₹741.00 per share . The lot size for an application is 20. The minimum amount of investment required by an retail is ₹14,100 (20 shares). The lot size investment for sNII is 14 lots (280 shares), amounting to ₹2,07,480, and for bNII, it is 68 lots (1,360 shares), amounting to ₹10,07,760.
The issue includes a reservation of up to 10,000 shares for employees offered at a discount of ₹70.00 to the issue price.
Kotak Mahindra Capital Co.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Concord Biotech IPO RHP for detailed Information.
| IPO Date | August 4, 2023 to August 8, 2023 |
| Listing Date | August 18, 2023 |
| Face Value | ₹1 per share |
| Issue Price Band | ₹705 to ₹741 per share |
| Issue Price Final | ₹741 per share |
| Lot Size | 20 Shares |
| Sale Type | Offer For Sale |
| Total Issue Size | 2,09,25,652 shares (aggregating up to ₹1,550.52 Cr) |
| Employee Discount | ₹70.00 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Post Issue | 10,46,16,204 shares |
Concord Biotech IPO offers total 2,09,25,652 shares. Out of which 1,04,57,825 (49.98%) allocated to QIB, 41,83,130 (19.99%) allocated to QIB, 31,37,348 (14.99%) allocated to NII, 73,20,479 (34.98%) allocated to RII and 62,74,695 (29.99%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 1,04,57,825 (49.98%) | NA |
| − Anchor Investor Shares Offered | 62,74,695 (29.99%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 41,83,130 (19.99%) | NA |
| NII (HNI) Shares Offered | 31,37,348 (14.99%) | NA |
| − bNII > ₹10L | 20,91,565 (10.00%) | 7,469 |
| − sNII < ₹10L | 10,45,783 (5.00%) | 3,734 |
| Retail Shares Offered | 73,20,479 (34.98%) | 3,66,023 |
| Employee Shares Offered | 10,000 (0.05%) | NA |
| Total Shares Offered | 2,09,25,652 (100.00%) |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Concord Biotech IPO raises ₹464.95 crore from anchor investors. Concord Biotech IPO Anchor bid date is August 3, 2023. Concord Biotech IPO Anchor Investors list
| Bid Date | August 3, 2023 |
| Shares Offered | 62,74,695 |
| Anchor Portion Size (In Cr.) | 464.95 |
| Anchor lock-in period end date for 50% shares (30 Days) | September 10, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | November 9, 2023 |
Concord Biotech IPO opens on August 4, 2023, and closes on August 8, 2023.
| IPO Open Date | Fri, Aug 4, 2023 |
| IPO Close Date | Tue, Aug 8, 2023 |
| Tentative Allotment | Fri, Aug 11, 2023 |
| Initiation of Refunds | Mon, Aug 14, 2023 |
| Credit of Shares to Demat | Thu, Aug 17, 2023 |
| Tentative Listing Date | Fri, Aug 18, 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on Tue, Aug 8, 2023 |
Investors can bid for a minimum of 20 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,820 |
| Retail (Max) | 13 | 260 | ₹1,92,660 |
| S-HNI (Min) | 14 | 280 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,340 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,360 | ₹10,07,760 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.
The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.
Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.
| Period Ended | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
| Assets | 1,182.55 | 1,312.80 | 1,513.98 |
| Total Income | 630.75 | 736.35 | 888.48 |
| Profit After Tax | 234.89 | 174.93 | 240.08 |
| Net Worth | 999.37 | 1,103.22 | 1,290.00 |
| Reserves and Surplus | |||
| Total Borrowing | 86.35 | 60.59 | 31.24 |
The market capitalization of Concord Biotech IPO is ₹7752.06 Cr.
The objectives of the Offer are to:
[Dilip Davda] The company is an Indian biopharma company with many niche products. It marked a setback in the bottom line for FY22 but posted growth in the top line for the reported three fiscals. Based on FY23 financial performance, the issue appears fully priced. This entire issue is by way of OFS and no fund is going to the company. Well-informed investors may park funds for the medium to long-term rewards. Read detail review...
| Listing Date | August 18, 2023 |
| BSE Script Code | 543960 |
| NSE Symbol | CONCORDBIO |
| ISIN | INE338H01029 |
| Final Issue Price | ₹741 per share |
Concord Biotech Ltd.
1482-86,
Trasad Road Dholka,
Ahmedabad – 382225
Ahmedabad, Gujarat
Phone: 079-6813 8700
Email: complianceofficer@concordbiotech.com
Website: http://www.concordbiotech.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: concordbiotech.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Concord Biotech IPO is a main-board IPO of 2,09,25,652 equity shares of the face value of ₹1 aggregating up to ₹1,550.52 Crores. The issue is priced at ₹741 per share. The minimum order quantity is 20.
The IPO opens on August 4, 2023, and closes on August 8, 2023.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Concord Biotech IPO using UPI as a payment gateway. Zerodha customers can apply in Concord Biotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Concord Biotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Concord Biotech IPO opens on August 4, 2023 and closes on August 8, 2023.
Concord Biotech IPO lot size is 20, and the minimum amount required for application is ₹14,820.
You can apply in Concord Biotech IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Concord Biotech IPO will be done on Friday, August 11, 2023, and the allotted shares will be credited to your demat account by Thursday, August 17, 2023. Check the Concord Biotech IPO allotment status.
The Concord Biotech IPO listing date is on Friday, August 18, 2023.
Useful Articles
RHP